NIKKEI 225
28,009.35 -239.89 (-0.85%) HANG SENG
20,011.21 -34.56 (-0.17%) CRUDE OIL
90.47 -0.29 (-0.32%) GOLD FUTURES
1,802.50 -2.70 (-0.15%) DOW
32,832.54 +29.07 (+0.09%) BTC-GBP
19,717.55 +350.19 (+1.81%)
GH Dec 2022 210.000 call
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | 0.5500 |
| Ask | 4.7000 |
| Strike | 210.00 |
| Expiry date | 2022-12-16 |
| Day's range | 3.5000 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
- Business Wire
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
PALO ALTO, Calif., August 08, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.
- Business Wire
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
PALO ALTO, Calif., & CAMBRIDGE, Mass., August 08, 2022--Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results are being reported today at the International Association for the Study of Lung Cancer (IASLC)
- Motley Fool
Why Guardant Health Stock Was So Healthy Today
Investors are cheered by the company's latest set of quarterly results, in spite of a deeper net loss.
